Criticism of cancer treatment limitation

Regional health councils have been criticised by a team of prostate cancer specialists for preventing certain patients from receiving a new form of medication.

In approving treatment with the medication Xtandi, which costs 1,000 kroner per day to use, regional councils said it would not be made available to individuals who had already been treated with Zytiga, another form of medication.

Doctors said there was no medical argument for not treating prostate cancer with the new form of medication, leaving the only explanation for the decision to be financial considerations.

A spokesperson for regional councils said studies showed that giving both medications showed no benefit.


This story was included in The Copenhagen Post's Morning Briefing for Monday, September 10If you would like to receive stories like these delivered to your inbox by 8am each weekday, sign up for our Morning Briefing newsletter today.